Becerra-Tomás, NereaFitó Colomer, MontserratSalas Salvadó, Jordi2022-03-302022-03-302021Becerra-Tomás N, Ruiz-Canela M, Hernández-Alonso P, Bulló M, Li J, Guasch-Ferré M et al. Glycolysis metabolites and risk of atrial fibrillation and heart failure in the PREDIMED trial. Metabolites. 2021 May 11;11(5):306. DOI: 10.3390/metabo110503062218-1989http://hdl.handle.net/10230/52800The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.application/pdfeng© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/metabo11050306PREDIMED studyAtrial fibrillationGlycolysisHeart failureinfo:eu-repo/semantics/openAccess